Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record.

Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent

Open access
Natsuaki, Masahiro, Kozuma, Ken, Morimoto, Takeshi, Kadota, Kazushige, Muramatsu, Toshiya, Nakagawa, Yoshihisa, Akasaka, Takashi, Igarashi, Keiichi, Tanabe, Kengo, Morino, Yoshihiro, Ishikawa, Tetsuya, Nishikawa, Hideo, Awata, Masaki, Abe, Mitsuru, Okada, Hisayuki, Takatsu, Yoshiki, Ogata, Nobuhiko, Kimura, Kazuo, Urasawa, Kazushi, Tarutani, Yasuhiro, Shiode, Nobuo, Kimura, Takeshi · 2013 · Journal of the American College of Cardiology

Abstract

OBJECTIVES: NEXT (NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial) was designed for evaluating the noninferiority of a biolimus-eluting stent (BES) relative to an everolimus-eluting stent (EES) in terms of target lesion revascularization (TLR) at 1 year. BACKGROUND: Efficacy and safety data comparing biodegradable polymer BES with durable polymer cobalt-chromium EES are currently limited. METHODS: The NEXT trial is a prospective, multicenter, randomized, open-label, noninferiority trial comparing BES with EES. Between May and October 2011, 3,235 patients were randomly assigned to receive either BES (n = 1,617) or EES (n = 1,618). RESULTS: At 1 year, the primary efficacy endpoint of TLR occurred in 67 patients (4.2%) in the BES group, and in 66 patients (4.2%) in the EES group, demonstrating noninferiority of BES relative to EES (p for noninferiority <0.0001, and p for superiority = 0.93). Cumulative incidence of definite stent thrombosis was low and similar between the 2 groups (0.25% vs. 0.06%, p = 0.18). An angiographic substudy enrolling 528 patients (BES: n = 263, and EES: n = 265) demonstrated noninferiority of BES relative to EES regarding the primary angiographic endpoint of in-segment late loss (0.03 ± 0.39 mm vs. 0.06 ± 0.45 mm, p for noninferiority <0.0001, and p for superiority = 0.52) at 266 ± 43 days after stent implantation. CONCLUSIONS: One-year clinical and angiographic outcome after BES implantation was noninferior to and not different from that after EES implantation in a mostly stable coronary artery disease population. One-year clinical outcome after both BES and EES use was excellent, with a low rate of TLR and extremely low rate of stent thrombosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.04.045

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 205

Metadata

Authors
Natsuaki, M., Kozuma, K., Morimoto, T., Kadota, K., Muramatsu, T., Nakagawa, Y., Akasaka, T., Igarashi, K., Tanabe, K., Morino, Y., Ishikawa, T., Nishikawa, H., Awata, M., Abe, M., Okada, H., Takatsu, Y., Ogata, N., Kimura, K., Urasawa, K., Tarutani, Y., Shiode, N., & Kimura, T.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2013-07
Volume
62
Issue
3
Pages
181-190
ISSN
0735-1097 (ISSN-L)
OpenAlex
W96070148
Cited by
205
References
0
FWCI
30.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent. https://app.cochat.ai/papers/10.1016/j.jacc.2013.04.045
The paper
Natsuaki, M., Kozuma, K., Morimoto, T., Kadota, K., Muramatsu, T., Nakagawa, Y., Akasaka, T., Igarashi, K., Tanabe, K., Morino, Y., Ishikawa, T., Nishikawa, H., Awata, M., Abe, M., Okada, H., Takatsu, Y., Ogata, N., Kimura, K., Urasawa, K., . . . Kimura, T. (2013). Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2013.04.045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.